Trials of a potential blockbuster cholesterol drug were halted after a safety board found the drug actually increased cardiovascular deaths.
The drug, made by Pfizer, was designed to increase levels of good cholesterol, which might lower the amount of plaque in heart arteries.
15,000 volunteers participated in the international study.
Half took the drug in combination with Lipitor, a drug that lowers bad cholesterol levels.
The other half took Lipitor alone.
An independent review board counted 82 deaths in the new drug group, compared to 51 deaths in the other group.
This drug was anticipated to be a new way to battle heart disease.